Century Therapeutics (IPSC) Free Cash Flow (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Free Cash Flow data on file, last reported at -$25.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 26.36% year-over-year to -$25.8 million in Q1 2026; TTM through Mar 2026 was -$95.5 million, a 17.14% increase from a year earlier, with the FY2025 full-year figure at -$104.7 million, up 5.02% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$25.8 million, down from -$16.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for IPSC reached as high as $82.7 million in Q1 2022 and fell as low as -$36.0 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$19.5 million across 5 years, with a median of -$27.2 million in 2023.
• Across the five-year window, Free Cash Flow jumped 443.62% in 2022 and slumped 2121.22% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$1.2 million in 2022, then slumped by 2121.22% to -$27.2 million in 2023, then grew by 10.98% to -$24.2 million in 2024, then surged by 34.1% to -$16.0 million in 2025, then plunged by 61.92% to -$25.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$25.8 million in Q1 2026, -$16.0 million in Q4 2025, and -$25.8 million in Q3 2025.